Here are monday's biggest analyst calls of the day: tesla, hershey, rh & more

(This story is for CNBC PRO subscribers only.) Here are the biggest calls on Wall Street on Monday: Guggenheim upgraded Bristol Myers to buy from neutral Guggenheim upgraded the

pharmaceutical company and said it was bullish on the company's cancer drug, Opdivo. "The series of recent positive Ph 3 datasets for Opdivo suggest that growth of the

immuno-oncology franchise will return in 2021 and accelerate in 2022, removing a pillar of our neutral stance. With the shares trading at just 8.3x our 2021 forecast with several potential

2021/22 upside catalysts not in our model we view the risk/reward in BMY as attractive and institute a PT of $70/shr." Jefferies initiated RH as underperform Jefferies initiated the

home-furnishing company as underperform and said that RH 's international strategy was risky. "Management's pursuit of the 'path less traveled' has largely worked

the past few years, but we see inherent execution risk in the go-forward strategy with 9% downside to F'22E Street EPS. Plus, as a furniture business with 99% domestic exposure, we have

difficulty justifying a market multiple on par with luxury goods players that have global brand validation." Bank of America downgraded VF Corp to underperform from neutral Bank of

America downgraded the apparel and footwear maker and owner of brands like Vans and North Face and said that Vans was losing market share due to Nike's "reemergence." "We

downgrade VF Corp to Underperform as we believe Vans' slowdown in the U.S. is likely to restrain valuation. VFC reported F3Q adj. EPS of $0.67 but Van's revenue declined 11% led

by a 17% decline in the Americas. Vans' recovery in the U.S. has lagged peers including NKE as we believe Vans is losing market share at retail in the U.S. from Nike's

reemergence." Citi initiated Hershey as buy Citi initiated the chocolate and candy maker and called it a "attractive" long-term holding. "HSY plays in attractive

categories that grow faster (even in the US) than most other packaged food categories. Overseas, HSY is a smaller player in its core categories, but we believe the company has significant

potential for future growth. The company's profit margins are higher than those of its peers and it has less leverage." Wedbush raised its price target on Tesla to $500 from $475

Wedbush raised its price target on the stock ahead of the company's earnings report later this week and said Tesla was facing another "show me" quarter. "With Tesla

already reporting 3Q deliveries which came in above Street expectations, now all the Street's focus around earnings on Wednesday will be gauging the level of profitability and unit

growth trajectory into 4Q. To this point, we believe Tesla's improved manufacturing efficiency and shining Giga 3 success in China will be on full display later this week and lead to

another strong bottom-line performance which should beat the Street in our opinion." Argus downgraded UnitedHealth to hold from buy Argus downgraded the health insurance company and

said it was "concerned" about declining enrollment in commercial plans due to unemployment among other things. "We expect UnitedHealth to face pressure from rising medical

utilization and higher costs for COVID-19 treatments, vaccines and testing. We are also concerned about declining enrollment in UnitedHealthcare commercial plans due to private-sector job

losses. The combination of rising utilization and reduced enrollment could pressure margins in the coming quarters."